{"doi":"10.1101/2023.09.28.23296246","title":"Impact of Fludrocortisone on the Outcomes of Subarachnoid Hemorrhage Patients: A Retrospective Analysis","abstract":"Background: Whether the use of fludrocortisone affects outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH) and its usage rate in the United States remain unknown. Methods: We conducted a retrospective analysis of 78 consecutive patients with a ruptured aSAH at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. We adjusted the primary outcome for age, hypertension, aSAH grade, and time from aSAH onset to aneurysm treatment. Secondary outcomes were brain and cardiopulmonary dysfunction events. Results: Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 64% were female, and 41 (53%) received fludrocortisone. The adjusted common odds ratio, aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95% CI, 0.14-0.80; P=0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different: delayed cerebral ischemia (22% vs. 39%, P=0.16); cardiac dysfunction (0% vs. 11%; P=0.10); and pulmonary edema (15% vs. 8%; P=0.59). Conclusions: The risk of disability or death at 90 days was lower with the use of fludrocortisone in aSAH patients.","journal":"medRxiv","year":2023,"id":412030,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8702,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1192964,"name":"Janki Naidugari","orcid":null,"position":1,"is_corresponding":false},{"id":376849,"name":"Michael J. Feldman","orcid":"0000-0002-8979-3128","position":2,"is_corresponding":false},{"id":1192965,"name":"Jordan A. Magarik","orcid":null,"position":3,"is_corresponding":false},{"id":668163,"name":"Dale Ding","orcid":"0000-0002-2627-446X","position":4,"is_corresponding":false},{"id":509580,"name":"Isaac Josh Abecassis","orcid":"0000-0003-0511-806X","position":5,"is_corresponding":false},{"id":264405,"name":"Matthew W. Semler","orcid":"0000-0002-7664-8263","position":6,"is_corresponding":false},{"id":105997,"name":"Todd W. Rice","orcid":"0000-0002-7136-5408","position":7,"is_corresponding":false},{"id":353771,"name":"Akshitkumar M. Mistry","orcid":"0000-0002-7918-5153","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T01:21:46.548301Z","pmid":"37808869","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}